MX2023007301A - Moleculas bifuncionales anti-pd1/il-7. - Google Patents
Moleculas bifuncionales anti-pd1/il-7.Info
- Publication number
- MX2023007301A MX2023007301A MX2023007301A MX2023007301A MX2023007301A MX 2023007301 A MX2023007301 A MX 2023007301A MX 2023007301 A MX2023007301 A MX 2023007301A MX 2023007301 A MX2023007301 A MX 2023007301A MX 2023007301 A MX2023007301 A MX 2023007301A
- Authority
- MX
- Mexico
- Prior art keywords
- molecules
- bifunctional anti
- bifunctional
- variant
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2020/086600 WO2021122866A1 (en) | 2019-12-17 | 2020-12-17 | Bifunctional molecules comprising an il-7 variant |
| EP21305462 | 2021-04-09 | ||
| EP21200350 | 2021-09-30 | ||
| PCT/EP2021/086471 WO2022129512A1 (en) | 2020-12-17 | 2021-12-17 | Bifunctional anti-pd1/il-7 molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007301A true MX2023007301A (es) | 2023-07-04 |
Family
ID=79024880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007301A MX2023007301A (es) | 2020-12-17 | 2021-12-17 | Moleculas bifuncionales anti-pd1/il-7. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240067727A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4263606A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023554097A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230129441A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021402065A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3201729A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303745A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023007301A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022129512A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022307460A1 (en) * | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| US20240424127A1 (en) * | 2023-01-11 | 2024-12-26 | Bright Peak Therapeutics Ag | Il-7 polypeptides, immunocytokines comprising same, and uses thereof |
| CN118359730A (zh) * | 2023-01-17 | 2024-07-19 | 上海君赛生物科技有限公司 | 包含细胞因子的靶向型融合蛋白 |
| WO2026052654A1 (en) * | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| KR101163424B1 (ko) * | 2003-12-30 | 2012-07-13 | 메르크 파텐트 게엠베하 | Il-7 융합 단백질 |
| CN101072793B (zh) | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| JP2009542592A (ja) * | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−2媒介性免疫応答の有効性を高める組成物および方法 |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| EP3587448B1 (en) | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗pd−1抗体及びその使用方法 |
| EP3402255B1 (en) | 2016-02-02 | 2021-03-31 | Huawei Technologies Co., Ltd. | Emission power verification method, user equipment, and base station |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| MX2019002946A (es) | 2016-09-14 | 2019-09-26 | Abbvie Biotherapeutics Inc | Anticuerpos anti-pd-1 y sus usos. |
| JP7102670B2 (ja) * | 2018-01-25 | 2022-07-20 | アイ-エムエービー バイオファーマ ユーエス リミテッド | 抗pd‐l1抗体とil‐7との融合 |
| KR20210003814A (ko) * | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
| CA3097593A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| US11491838B2 (en) | 2018-07-10 | 2022-11-08 | Iveco S.P.A. | Suspension for a vehicle |
| WO2020127377A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| AU2019406452B2 (en) | 2018-12-21 | 2021-09-16 | Ose Immunotherapeutics | Humanized anti-human-PD-1 antibody |
| CN110256583B (zh) * | 2019-07-11 | 2022-05-20 | 中国科学院生物物理研究所 | 一种il-2突变体与抗体的融合蛋白及其应用 |
| TW202136287A (zh) * | 2019-12-17 | 2021-10-01 | 法商Ose免疫治療公司 | 包含il-7變體之雙官能分子 |
-
2021
- 2021-12-17 AU AU2021402065A patent/AU2021402065A1/en active Pending
- 2021-12-17 CA CA3201729A patent/CA3201729A1/en active Pending
- 2021-12-17 EP EP21831061.3A patent/EP4263606A1/en active Pending
- 2021-12-17 US US18/267,795 patent/US20240067727A1/en active Pending
- 2021-12-17 JP JP2023537140A patent/JP2023554097A/ja active Pending
- 2021-12-17 MX MX2023007301A patent/MX2023007301A/es unknown
- 2021-12-17 WO PCT/EP2021/086471 patent/WO2022129512A1/en not_active Ceased
- 2021-12-17 IL IL303745A patent/IL303745A/en unknown
- 2021-12-17 KR KR1020237023523A patent/KR20230129441A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4263606A1 (en) | 2023-10-25 |
| JP2023554097A (ja) | 2023-12-26 |
| IL303745A (en) | 2023-08-01 |
| WO2022129512A1 (en) | 2022-06-23 |
| CA3201729A1 (en) | 2022-06-23 |
| AU2021402065A1 (en) | 2023-06-29 |
| KR20230129441A (ko) | 2023-09-08 |
| US20240067727A1 (en) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020127377A9 (en) | Bifunctional anti-pd-1/il-7 molecule | |
| ZA201902141B (en) | Acid-alpha glucosidase variants and uses thereof | |
| PH12021550905A1 (en) | Antiviral prodrugs and nanoformulations thereof | |
| AU201816232S (en) | Water purifier | |
| ZA201902140B (en) | Acid-alpha glucosidase variants and uses thereof | |
| MX2023011964A (es) | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. | |
| PH12021551425A1 (en) | Bifunctional anti-pd-1/sirpa molecule | |
| PH12021550102A1 (en) | Cardiosafe antidiabetic therapy | |
| MX2019010950A (es) | Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso. | |
| GB2607806B (en) | Generating event output. | |
| EP4417262A3 (en) | Combination therapy | |
| WO2019108871A8 (en) | Biofouling resistant coatings and methods of making and using the same | |
| PH12018502233A1 (en) | ErbB INHIBITORS AND USES THEREOF | |
| MX2021003159A (es) | Microemulsiones que contienen antioxidantes. | |
| SE1650923A1 (en) | An elongate weld and a beam having such a weld | |
| WO2020130652A3 (ko) | 세균을 용균하는 신규한 박테리오파지 | |
| PH12022551413A1 (en) | Bifunctional molecules comprising an il-7 variant | |
| PH12020500266A1 (en) | Therapeutic or non-therapeutic use of protozoans of the willaertia genus as a fungistatic and/or fungicide | |
| SG10201806014TA (en) | Feedback canceller and hearing aid | |
| PH12018000199B1 (en) | Compositions containing polymeric carbodiimide, epoxide and polyester-based polymers, their production and use | |
| WO2022046669A3 (en) | A nuclease and application thereof | |
| MX2024003331A (es) | Moleculas de union a d3 y usos de estas. | |
| MX2022005034A (es) | Combinacion farmaceutica y uso de la misma. | |
| WO2021108472A3 (en) | Novel organoleptic compounds | |
| MX2021004804A (es) | Compuestos organolepticos novedosos. |